Breast cancer signaling proteins

Breast cancer signaling proteins represent a broad and diverse class of molecular entities that drive the initiation, progression, and survival of breast malignancies. This category encompasses cell surface receptors like Human Epidermal Growth Factor Receptor 2 (HER2), which triggers downstream proliferative pathways, and nuclear receptors such as the Estrogen Receptor (ER) that regulate gene expression in response to hormonal stimuli (National Cancer Institute, 2023). Additionally, it includes critical intracellular mediators like the PI3K/AKT/mTOR pathway components and cell cycle regulators such as Cyclin-Dependent Kinases 4 and 6 (CDK4/6) (PubMed, 2022). These proteins are central to the molecular subtyping of breast cancer, which determines the selection of targeted therapies like monoclonal antibodies, endocrine treatments, and small-molecule kinase inhibitors (StatPearls, 2023). Because these proteins govern essential cellular processes including DNA repair and apoptosis, they are frequently mutated or overexpressed in tumor cells to evade normal growth constraints (UniProt, 2024). Consequently, this term is considered a functional grouping of multiple distinct therapeutic targets rather than a single specific molecule.

Other names

Breast cancer molecular targetsBreast cancer signaling pathwaysMammary carcinoma signaling molecules

This entry refers to a heterogeneous group of proteins rather than a single target. Mechanisms of action for drugs targeting these proteins include the inhibition of receptor tyrosine kinases (e.g., HER2), competitive antagonism or degradation of nuclear hormone receptors (e.g., Estrogen Receptor), selective inhibition of cyclin-dependent kinases (CDK4/6) to induce cell cycle arrest, and inhibition of PARP enzymes to prevent DNA repair in BRCA-deficient cells (Nature Reviews Cancer, 2021; StatPearls, 2023).